{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:19:52Z","timestamp":1788200392288,"version":"build-2803163510"},"reference-count":11,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T00:00:00Z","timestamp":1547769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Dermatology"],"published-print":{"date-parts":[[2019,3]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Acne vulgaris (acne) is a common skin condition in children and adolescents. Efficacy of tretinoin is well documented in studies that included pediatric patients (12\u201018\u00a0years of age). With acne routinely presenting in younger patients, data are needed in this important group. Lotion formulations are commonly used across dermatology and are well liked by patients.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the safety and efficacy of a novel once\u2010daily tretinoin 0.05% lotion in preadolescent subjects (\u2264\u00a013\u00a0years) with moderate\u2010to\u2010severe acne.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Post hoc analysis of two multicenter, randomized, double\u2010blind, vehicle\u2010controlled phase 3 studies in moderate\u2010to\u2010severe acne. Preadolescent subjects (N\u00a0=\u00a0154) randomized (1:1) to receive tretinoin 0.05% lotion or vehicle, once daily for 12\u00a0weeks. Efficacy assessments included changes in baseline inflammatory\/noninflammatory lesions and treatment success (at least 2\u2010grade reduction in Evaluator's Global Severity Score [EGSS] and clear\/almost clear). Safety, adverse events (AEs), and cutaneous tolerability evaluated throughout.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n At Week 12, mean percent reduction in inflammatory and noninflammatory lesion counts were 49.5% and 44.0% compared with 31.4% and 18.8% with vehicle (both\n P<\/jats:italic>\n \u00a0=\u00a00.001). Treatment success was achieved by 23.7% of subjects by Week 12, compared with 7.2% (\n P<\/jats:italic>\n \u00a0=\u00a00.009). The majority of AEs were mild and transient: most frequently were application site pain (5.6%) and application site dryness (2.8%). Local cutaneous safety and tolerability assessments were generally mild\u2010to\u2010moderate and improved by Week 12.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Tretinoin 0.05% lotion was significantly more effective than vehicle in achieving treatment success and reducing inflammatory and noninflammatory lesions in preadolescent acne. It was well tolerated, with all treatment\u2010related AEs deemed mild or moderate.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/pde.13744","type":"journal-article","created":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T04:30:13Z","timestamp":1547785813000},"page":"193-199","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Novel tretinoin 0.05% lotion for the once\u2010daily treatment of moderate\u2010to\u2010severe acne vulgaris in a preadolescent population"],"prefix":"10.1111","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2760-0474","authenticated-orcid":false,"given":"Lawrence F.","family":"Eichenfield","sequence":"first","affiliation":[{"name":"Departments of Dermatology and Pediatrics University of California, San Diego School of Medicine and Rady Children's Hospital San Diego California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Sugarman","sequence":"additional","affiliation":[{"name":"University of California San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Guenin","sequence":"additional","affiliation":[{"name":"Ortho Dermatologics Bridgewater New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Harris","sequence":"additional","affiliation":[{"name":"Bausch Health Bridgewater New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varsha","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Dow Pharmaceutical Sciences Inc. Petaluma California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,1,18]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(97)70307-X"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2008.06741.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04276.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.02.009"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/1203475415591117"},{"issue":"4","key":"e_1_2_8_7_1","first-page":"466","article-title":"Evaluating tretinoin formulations in the treatment of acne","volume":"13","author":"Kircik LH","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2008.00688.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2009-3447"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2012.01811.x"},{"issue":"6","key":"e_1_2_8_11_1","first-page":"305","article-title":"Comparison of micronized tretinoin gel 0.05% and tretinoin gel microsphere 0.1% in young adolescents with acne: a post hoc analysis of efficacy and tolerability data","volume":"87","author":"Lucky AW","year":"2011","journal-title":"Cutis"},{"issue":"10","key":"e_1_2_8_12_1","first-page":"602","article-title":"Novel tretinoin 0.05% lotion for the once\u2010daily treatment of moderate\u2010to\u2010severe acne vulgaris: assessment of efficacy and safety in patients aged 9\u00a0years and older","volume":"17","author":"Tyring SK","year":"2018","journal-title":"J Drugs Dermatol"}],"container-title":["Pediatric Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpde.13744","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pde.13744","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/pde.13744","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pde.13744","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:37:31Z","timestamp":1694392651000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pde.13744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,18]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1111\/pde.13744"],"URL":"https:\/\/doi.org\/10.1111\/pde.13744","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734881432.793556352","asserted-by":"object"}]},"ISSN":["0736-8046","1525-1470"],"issn-type":[{"value":"0736-8046","type":"print"},{"value":"1525-1470","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,18]]},"assertion":[{"value":"2019-01-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}